Neurotech International Limited

Equities

NTI

AU000000NTI9

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 11:45:46 2026-01-13 pm EST			5-day change	1st Jan Change
0.0140 ^AUD	+7.69%		-6.67%	-

Dec. 16	Neurotech International receives A$4 million placement commitments	RE
Dec. 14	Neurotech International requests trading halt pending capital raising announcement	RE

Neurotech International Limited Announces Change of Registered Address and Principal Place of Business

Published on 07/10/2025 at 05:20 am EDT

S&P Capital IQ

Neurotech International Limited

+7.69%

Neurotech International Limited announced that in accordance with ASX Listing Rule 3.14, the address of its registered office and its principal place of business will change, effective immediately. The Company's new details will be, as follows: Registered Address & Principal Place of Business: Suite 102 /Level 1, 55 Collins Street, Melbourne, VIC 3000.

Latest news about Neurotech International Limited

Dec. 16	Neurotech International receives A$4 million placement commitments	RE
Dec. 14	Neurotech International requests trading halt pending capital raising announcement	RE
25-10-07	Neurotech International gets US FDA rare pediatric disease designation for NTI164	RE
25-10-07	Neurotech International Secures FDA Rare Pediatric Disease Designation for Rett Syndrome Drug	MT
25-09-23	Neurotech Starts Authorized Prescriber Program for Autism Therapy Candidate, Shares Up 6%	MT
25-09-11	ASX Biggest Losers	MT
25-08-29	Neurotech International Limited Reports Earnings Results for the Full Year Ended June 30, 2025	CI
25-08-29	Neurotech International posts FY loss attributable A$10.6 million	RE
25-08-28	Neurotech International Limited Auditor Raises 'Going Concern' Doubt	CI
25-07-10	Neurotech International Limited Announces Change of Registered Address and Principal Place of Business	CI
25-06-16	Neurotech International Appoints Chief Medical Advisor in the US	MT
25-06-15	Neurotech International Limited Appoints Dr. Bonni Goldstein as Chief Medical Advisor Usa	CI
25-05-05	Neurotech International Says Oral Toxicology Studies of NTI164 Drug Candidate Demonstrate No Safety Concerns	MT
25-04-01	Thomas Duthy Resigns as an Executive Director of Neurotech International Limited	CI
25-03-30	Neurotech's Drug Candidate Receives Orphan Drug Status from European Commission; Shares Rise 3%	MT
25-03-30	Neurotech International Says European Commission Grants NTI164 Orphan Drug Designation	RE
25-02-27	Neurotech International Logs HY Loss From Ordinary Activities A$7.445 Mln	RE
25-02-27	Neurotech International Says European Medicines Agency Issued Positive Opinion On Orphan Medicinal Product Designation Application Of NTI164	RE
25-02-27	Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2024	CI
25-02-13	Neurotech International Signs Cannabis-Based Product Development Deal	MT
25-02-12	Neurotech International Signs Development Agreement For Cannabinoid Therapies	RE
25-02-04	Neurotech International Limited Appoints Anthony Filippis as Director	CI
24-12-02	Neurotech International Limited Announces Resignation of Erlyn Dawson as Joint Company Secretary	CI
24-11-25	Neurotech Secures Ethics Approval for Study of Cannabis-Based Drug Candidate in Adults; Shares Up 8%	MT
24-11-14	ASX Small-Cap Stocks to Watch	MT

Chart Neurotech International Limited

Duration

Period

NTI: Dynamic Chart

Company Profile

Neurotech International Limited is an Australia-based clinical-stage biopharmaceutical development company. The Company is focused predominately on pediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. It has completed a Phase II/III randomized, double-blind, placebo-controlled clinical trial in autism spectrum disorder (ASD) with clinically significant benefits reported across a number of clinically validated measures and safety. In addition, it has completed and reported significant and clinically meaningful Phase I/II trials in ASD and pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. NTI164 is being developed as a therapeutic drug product for a range of neurological disorders in children where neuroinflammation is involved.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 02 - Q2 2026 Earnings Release (Projected)

More about the company